Speculative Long on Inventiva (IVA): Capturing MASH Momentum Around EASL and NATiV3 Build-up
Inventiva (IVA) is a clinical-stage biotech developing lanifibranor, a pan-PPAR oral therapy for metabolic dysfunction-associated steatohepatitis (MASH). With $230.9M in cash and short-term deposits, a market cap near $1.14B, an EASL presentation on 05/27/2026 - 05/30/2026, and a Phase 3 top-line due in Q4 2026, the stock looks like a speculative l…